Aerie Pharmaceuticals, Inc. (AERI): Price and Financial Metrics


Aerie Pharmaceuticals, Inc. (AERI)

Today's Latest Price: $12.75 USD

0.36 (2.91%)

Updated Dec 2 4:00pm

Add AERI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AERI Stock Summary

  • With a one year PEG ratio of 147.91, Aerie Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 80.37% of US stocks.
  • With a price/sales ratio of 6.98, Aerie Pharmaceuticals Inc has a higher such ratio than 79.88% of stocks in our set.
  • Revenue growth over the past 12 months for Aerie Pharmaceuticals Inc comes in at 39.25%, a number that bests 87.43% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to AERI, based on their financial statements, market capitalization, and price volatility, are DMRC, CLXT, ARLO, TRXC, and PSTG.
  • AERI's SEC filings can be seen here. And to visit Aerie Pharmaceuticals Inc's official web site, go to www.aeriepharma.com.

AERI Stock Price Chart Interactive Chart >

Price chart for AERI

AERI Price/Volume Stats

Current price $12.75 52-week high $26.26
Prev. close $12.39 52-week low $9.01
Day low $12.15 Volume 265,744
Day high $12.85 Avg. volume 849,626
50-day MA $11.58 Dividend yield N/A
200-day MA $13.34 Market Cap 596.89M

Aerie Pharmaceuticals, Inc. (AERI) Company Bio


Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company was founded in 2005 and is based in Irvine, California.


AERI Latest News Stream


Event/Time News Detail
Loading, please wait...

AERI Latest Social Stream


Loading social stream, please wait...

View Full AERI Social Stream

Latest AERI News From Around the Web

Below are the latest news stories about Aerie Pharmaceuticals Inc that investors may wish to consider to help them evaluate AERI as an investment opportunity.

Molina Acquires Affinity, And Other News: The Good, Bad And Ugly Of Biopharma

Molina Healthcare announces acquisition of Affinity Health Plan Molina Healthcare Inc. (MOH) announced that it has inked a definitive agreement for acquiring substantially all of the assets of Affinity Health Plan. The purchase price is pegged to be nearly $380 million, net of expected tax benefits and inclusive of an...

Avisol Capital Partners on Seeking Alpha | October 1, 2020

FDA OKs Aerie Pharma's Rhopressa production facility in Ireland

The FDA has approved Aerie Pharmaceuticals' (AERI) sterile fill production facility in Athlone, Ireland for production of Rhopressa (netarsudil ophthalmic solution) 0.02% for commercial distribution in the U.S. The company started shipping Rocklatan to the U.S. earlier in Q3 2020, and has also manufactured supplies of Rhopressa for upcoming Phase 3 clinical trials in Japan.AERI...

Seeking Alpha | September 15, 2020

Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that its sterile fill production facility in Athlone, Ireland has received approval from the U.S. Food and Drug Administration (FDA) for production of Rhopressa® (netarsudil ophthal

Business Wire | September 15, 2020

Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the second quarter ended June 30, 2020 and provided a general business update. “Our second quarter results highlight the continued demand for both products in ou

Business Wire | August 6, 2020

Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its second quarter 2020 financial results will be released after the market closes on Thursday, August 6, 2020. Following the release, the Company will host a live conference ca

Business Wire | July 30, 2020

Read More 'AERI' Stories Here

AERI Price Returns

1-mo 16.12%
3-mo 12.24%
6-mo -15.34%
1-year -33.18%
3-year -80.35%
5-year -48.80%
YTD -47.25%
2019 -33.05%
2018 -39.58%
2017 57.86%
2016 55.44%
2015 -16.58%

Continue Researching AERI

Want to see what other sources are saying about Aerie Pharmaceuticals Inc's financials and stock price? Try the links below:

Aerie Pharmaceuticals Inc (AERI) Stock Price | Nasdaq
Aerie Pharmaceuticals Inc (AERI) Stock Quote, History and News - Yahoo Finance
Aerie Pharmaceuticals Inc (AERI) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8769 seconds.